Exclusive: Imperva seeks investment bank to explore options - sources

Nomura Securities Cuts Price Target on Imperva (IMPV) Following Preliminary 2Q Results

Nomura Securities maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $55.00 (from $60.00), following the company's preliminary 2Q financial results. IMPV is expecting revenue to be in the range of $57.5-58.0mn, an 8% growth yoy. This is down from the previous revenue... More

Oppenheimer Remains Bullish on Imperva (IMPV) Following a Disappointing 2Q Pre-Announcement

Oppenheimer reiterated an Outperform rating and $60.00 price target on Imperva (NYSE: IMPV) following the company's 2Q pre-announcement. Revenue was guided in the range of $57.5-58M from previous guidance of $65.5-66.5M. LPS was guided $(0.20)-(0.22) from $(0.02)-(0.04). IMPV's weak performance was primarily driven by customers'... More

Deutsche Bank Downgrades Imperva (IMPV) to Hold

Deutsche Bank downgraded Imperva (NYSE: IMPV) from Buy to Hold with a price target of $43.00 (from $45.00). The change follow disappointing preliminary Q2 results.

"IMPV negatively pre-announced its Q216 numbers, and blamed longer sales cycles and smaller deals sizes for the weakness in... More

Imperva (IMPV) Min. Price Seen at $55-$65/Share - BTIG

BTIG maintained a Buy rating on Imperva (NYSE: IMPV) with a price target of $55. Analyst Joel P. Fishbein thinks asset sales appear likely in today's robust M&A environment.

"Reuters reported that Imperva was interviewing investment banks for help in exploring strategic options after... More

Imperva (IMPV) Gains as Elliott Presses Company to Explore a Sale

Imperva (NYSE: IMPV) is gaining modestly (+2%) in pre-open trade Monday following reports late Friday from Reuters the company has hired an investment bank to help it explore strategic options amid pressure from activist hedge fund Elliott Management, citing people familiar with the... More